DSC
CRSP icon

Duncker Streett & Co’s CRISPR Therapeutics CRSP Stock Holding History

Duncker Streett & Co’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$600 Hold
11
– – ﹤0.01% 495
2026
Q1 		$523 Hold
11
– – ﹤0.01% 511
2025
Q4 		$577 Hold
11
– – ﹤0.01% 513
2025
Q3 		$713 Hold
11
– – ﹤0.01% 514
2025
Q2 		$535 Hold
11
– – ﹤0.01% 500
2025
Q1 		$374 Hold
11
– – ﹤0.01% 490
2024
Q4 		$433 Hold
11
– – ﹤0.01% 519
2024
Q3 		$517 Hold
11
– – ﹤0.01% 472
2024
Q2 		$594 Hold
11
– – ﹤0.01% 468
2024
Q1 		$750 Hold
11
– – ﹤0.01% 461
2023
Q4 		$689 Hold
11
– – ﹤0.01% 469
2023
Q3 		$499 Hold
11
– – ﹤0.01% 471
2023
Q2 		$618 Hold
11
– – ﹤0.01% 484
2023
Q1 		$498 Hold
11
– – ﹤0.01% 471
2022
Q4 		$447 Hold
11
– – ﹤0.01% 496
2022
Q3 		$1K Hold
11
– – ﹤0.01% 448
2022
Q2 		$1K Hold
11
– – ﹤0.01% 459
2022
Q1 		$1K Hold
11
– – ﹤0.01% 460
2021
Q4 		$1K Hold
11
– – ﹤0.01% 493
2021
Q3 		$1K Buy
+11
New +$1.38K ﹤0.01% 494

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Duncker Streett & Co's CRSP Position: Q2 2026 in Review

Duncker Streett & Co held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 11 shares worth $600. The position accounts for ﹤0.01% of the portfolio, ranked #495.

Duncker Streett & Co first reported a position in CRSP in Q3 2021 and has held it in 20 quarters since. The position peaked at $1K in Q3 2022. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Duncker Streett & Co held 11 shares of CRISPR Therapeutics worth $600 as of Q2 2026.
  • Duncker Streett & Co left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Duncker Streett & Co's portfolio in Q2 2026, its #495 holding.
  • Duncker Streett & Co first reported a position in CRISPR Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • Duncker Streett & Co's CRISPR Therapeutics position peaked at $1K in Q3 2022.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Duncker Streett & Co's 13F filing for Q2 2026, filed 28 Jul 2026.